Shoulder Innovations (SI) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
10 Jun, 2026Market opportunity and industry trends
Global annual shoulder arthroplasty market estimated at $2.8B, with strong growth expected, especially in outpatient and ASC settings.
Shoulder pain is highly prevalent, with 1 in 5 people over 65 in the U.S. affected and 8+ million annual physician visits.
Shoulder arthroplasty is one of the fastest-growing MedTech segments, with U.S. procedures projected to reach ~250,000 in 2025.
Market is shifting toward reverse total shoulder arthroplasty (rTSA), now comprising over 70% of procedures.
Product innovation and clinical differentiation
InSet Glenoid implant addresses glenoid loosening, a major complication in shoulder arthroplasty, with 100% implant survivorship and 87% reduction in "rocking horse" motion.
InSet technology enables seamless interchangeability between anatomic and reverse procedures, simplifying revision and conversion surgeries.
ProVoyance 3D AI/ML-enabled platform enhances preoperative planning with patient-specific anatomical renderings.
Capital-efficient instrument system reduces tray usage from up to 9 to just 2 per procedure, lowering costs and complexity.
Commercial strategy and growth drivers
Focused commercial approach targets ~1,800 high-volume surgeons performing the majority of procedures.
Integrated commercial leadership, surgeon education, and independent distributors drive adoption and retention.
Strategic partnership with INS introduces a micro-robotic platform, supporting robotics-as-a-service and ASC growth.
Expansion into new indications (fracture, metal sensitivity), adjacent markets (sports medicine, trauma), and select international markets.
Latest events from Shoulder Innovations
- Q1 2026 revenue surged 65% to $16.7M, with margin gains and a raised full-year outlook.SI
Q1 202613 May 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and risk oversight.SI
Proxy filing29 Apr 2026 - Vote on director elections and auditor ratification at the June 26, 2026 annual meeting.SI
Proxy filing29 Apr 2026 - Q4 revenue up 65% and 2026 guidance targets 31–37% growth, driven by innovation and ASC momentum.SI
Q4 202510 Mar 2026 - Innovative implants and AI-driven planning fuel rapid growth and high margins in shoulder arthroplasty.SI
Investor presentation10 Mar 2026 - AI-driven innovation and outpatient focus fuel strong growth and new opportunities in shoulder arthroplasty.SI
2026 CG Musculoskeletal Conference4 Mar 2026 - Disruptive InSet Glenoid and AI-driven platform fuel rapid growth in shoulder arthroplasty.SI
Investor presentation3 Mar 2026 - AI-driven planning and streamlined implants drive growth as ASC adoption accelerates.SI
Jefferies London Healthcare Conference 20253 Feb 2026 - 33% Q2 growth fueled by efficient two-tray system, ASC focus, and commercial scaling.SI
Morgan Stanley 23rd Annual Global Healthcare Conference31 Dec 2025